In Friday's The Good, The Bad, The Ugly: The biggest IPO ever makes its NYSE debut; U.S. taxes encourage foreign buyers; and tax inversion only goes one way.» Read More
Michael Ryan, UBS, takes a look at the quality of first quarter earnings and the outlook on the S&P 500 this year. At the end of the day it's about corporate profits and earnings, says Ryan.
Dan Morgan, Synovus Trust, shares his thoughts on Apple's new products and 7-for-1 stock split.
Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Dunkin' Brands plans to have 1,000 stores in the Golden State, reports CNBC's Jane Wells with a look at the company's expansion plans.
CNBC's Jim Cramer shares his thoughts on the legality of Bill Ackman's deal with Valeant to acquire Allergan, and why the SEC has an "existential crisis."
Jason Subotky, Yacktman Funds, shares his thoughts on Coca-Cola's equity compensation plan. The problem with these plans are they are complicated and a lot of the details are not fully flushed out, says Subotky.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
Anthony DiClemente, Nomura senior analyst, shares his upbeat outlook on the social media giant, as advertising dollars continue to shift towards digital media.
John Stephens, AT&T CFO, delves into Ma Bell's quarterly numbers and weighs in on the company's strategy to increase its wireless subscribers.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Boeing's profit margin on the commercial side improves to 11.8 percent, reports CNBC's Phil LeBeau with a break down on Boeing's quarterly results.
Jon Moeller, Procter & Gamble CFO, breaks down the company's third quarter results of $1.04 EPS ex-items on revenues of $20.56 billion and weighs in on where the company sees global growth.
Most of these investors are looking for a dialogue to improve value, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, sharing his thoughts on activist investors.
We overcame transport and weather issues in North American, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, breaking down his company's first quarter results of $0.79 EPS on revenues of $14.46 billion.
It's not a dirty little secret anymore, says Heather Thomson, Yummie by Heather Thomson founder, discussing how her company is redefining the shapewear industry and carving out a piece of the market.
Get the best of CNBC in your inbox